
Helena Beer
Editor at Hospital Healthcare Europe
Editor at Hospital Pharmacy Europe
Editor of Hospital Healthcare Europe & Hospital Pharmacy Europe @HHE_Digital @HPE_magazine
Articles
-
1 week ago |
hospitalpharmacyeurope.com | Ravijyot Saggu |Helena Beer
The National Child Mortality Database report on child deaths related to asthma and allergies was released in December 2024, providing sobering insights. Pharmacist Ravijyot Saggu offers an expert summary, emphasising key points from the thematic report and discussing necessary future actions.
-
2 weeks ago |
hospitalpharmacyeurope.com | Helena Beer
Non-adherence can negatively impact medication treatment strategies, particularly among oncology patients, driving up treatment costs while potentially worsening clinical outcomes. Although oral oncolytics offer convenience, they arguably require greater patient engagement in remembering to take their treatment, often resulting in lower adherence compared to infused therapies. Chronic lymphocytic leukaemia (CLL) is increasingly managed with long-duration, targeted oral treatments.
-
2 weeks ago |
hospitalpharmacyeurope.com | Helena Beer
A digital self-assessment tool designed to help hospital pharmacy teams take practical action to support sustainability and reduce the environmental impact of pharmacy services, pharmaceutical care and medicines, while supporting patient care, has been launched by the Royal Pharmaceutical Society (RPS).
-
2 weeks ago |
hospitalhealthcare.com | Helena Beer
With an introduction from Helena Beer, consultant gynaecologist Mr James Tibbott, lead clinician for gynaecology at Leeds Teaching Hospitals NHS Trust, discusses the Trust’s recent endometriosis centre recognition and the technology that helped them achieve it, how robotic surgery is transforming timely patient care and the latest research set to revolutionise diagnostics and treatment for this debilitating condition.
-
2 weeks ago |
hospitalpharmacyeurope.com | Helena Beer
Theranostics integrates diagnostic and therapeutic radiopharmaceuticals targeting the same molecular structures – delivering a ‘one-two punch’ for personalised cancer care. In his latest commentary, Professor Alain Astier discusses how the radionuclide 177Lu and 177Lu-based radioligands have gained traction in treating various conditions, including neuroendocrine tumours and metastatic prostate cancer.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 419
- Tweets
- 466
- DMs Open
- No

RT @HPE_magazine: Person-centred care has always been part of #pharmacy practice, but the @pharmacy_lnwh team has taken it to another level…

I'm thrilled to publish this case study about @pharmacy_lnwh's amazing #PersonCentredCare pilot. The team's passion and dedication is unparalleled and I had such a wonderful time interviewing @CeciliaTse_PCC @PareshHParmar1 & colleagues! Read it here ⤵️ https://t.co/EywoLHEywi

RT @OrchaHealth: Thanks to our friends @HHE_Digital @HelenaBeer27 for publishing this detailed interview with @LizAshallPayne about #digita…